Egyptian International Pharmaceutical Investments (CAI:PHAR) Research & Development: E£56 Mil (TTM As of Mar. 2026)


CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
69 GF Score
Price E£85.22
GF Value E£59.67
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments Research & Development?

Egyptian International Pharmaceutical Investments CAI:PHAR -3.71% 69 Research & Development is E£56 Mil as of Mar. 2026. GuruFocus rates CAI:PHAR with a GF Score™ of 69/100 and a GF Value™ of E£59.67 (Significantly Overvalued). The stock has 12 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Egyptian International Pharmaceutical Investments's Research & Development for the three months ended in Mar. 2026 was E£16 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was E£56 Mil.

Egyptian International Pharmaceutical Investments  (CAI:PHAR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Egyptian International Pharmaceutical Investments Research & Development Related Terms

Egyptian International Pharmaceutical Investments Research & Development Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments Research & Development Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 34.97 43.68 43.23 70.46

Egyptian International Pharmaceutical Investments Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.48 15.10 19.75 20.36 16.02
CAI:PHAR
69GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egyptian International Pharmaceutical Investments Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of E£56 Mil mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Research & Development of E£56 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Egyptian International Pharmaceutical Investments and its competitors.
Is Egyptian International Pharmaceutical Investments' Research & Development too high?
Egyptian International Pharmaceutical Investments' current Research & Development is E£56 Mil. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Research & Development compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' Research & Development of E£56 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Egyptian International Pharmaceutical Investments and its competitors. Egyptian International Pharmaceutical Investments's current Research & Development is E£56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.67, compared to a current price of E£85.22 — trading 42.8% above its estimated fair value. The current Research & Development is E£56 Mil. Egyptian International Pharmaceutical Investments' overall GF Score™ is 69/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Research & Development is E£56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£85.22 is trading 42.8% above its estimated GF Value™ of E£59.67. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • Research & Development: E£56 Mil
  • GF Value™: E£59.67 vs. price of E£85.22 (42.8% above fair value)
  • GF Score™: 69/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
69GF Score

Get the complete analysis for CAI:PHAR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£85.22
Price
E£59.67
GF Value